Monday, 16 November 2020

Intolerance vs.gene length

Why do some genes seem to withstand variants, and others do not?

In clinical genomics labs, determining which mutations are most likely to produce disease is a challenge. While some variants can occur in regions of the genome without any major consequences, others have a significant impact on gene protein structure and function, resulting in pathologies.


There are currently approaches that attempt to classify variants according to their probabilities of conferring risk of diseases. These methods include the measure of conservation at the phylogenetic level, the repercussion on protein structure depending on amino acid characteristics, or analysis of population allele frequency.


In 2013, Slave Petrovski and collaborators developed a gene-level assessment that ranked genes based on their likelihood to influence disease. This intolerance scoring system assesses which genes have more or less functional genetic variation than expected. The ranking of all genes can be obtained from this Excel table. This interesting paper can be summarized in the following figure (Figure 1). This study analyzed the existing variety of approximately 17,000 genes to compare the number of common variants that probably affect gene function against the total number of genetic variants per gene. According to their distribution, Petrovski and collaborators developed the Residual Variation Intolerance Score (RVIS). An RVIS less than 0 indicates that a gene has fewer common functional variants than expected; conversely, an RVIS greater than 0 indicates that a particular gene has fewer common functional variants that affect functions.



MUTATION TOLERANCE AND INTOLERANCE IN THE HUMAN GENOME

 A regression plot illustrating the relation between X, genes are plotted based on their number of all variants and Y, the number of common functionally relevant variants. Mutation-intolerant genes under the regression line and Mutation tolerant genes above the line.


After this study, a question emerged between my supervisor and me. Assuming, first, that there is a constant rate of mutation across all human genes, it follows that the longer a gene is, the more likely that this gene will become mutated. Second, most of the genes are functionally important, meaning they are intolerant to variants. So, should we expect that longer genes would have fewer functionally important regions?


To answer this question, we propose the following experiment: We will compare the intolerance scoring rank provided by Slave Petrovski and collaborators with the length of these genes. We explain our analysis step-by-step in this GitHub repository. The results obtained and discussion from this analysis are commented on in this blog post.


In the following scatter plot, we have represented the length of 15,742 genes against the RVIS. We have also used the bivariate correlation or Pearson correlation to measure the linear correlation between these two variables. The results provided (p=0.1629) tell us that there is no linear correlation between the length of a gene and the intolerance score.


 



Scatter diaphragm between gene length against RVIS. Notice both variables have been normalized. 



With the assumptions we made at the beginning, we expected to see a negative regression; longer genes should have a lower RVIS. However, the results obtained do not provide evidence for this theory. One reason could be because the assumptions we made are not completely correct. Mutation rate does vary across the genome. Another reason could be due to the methodology I followed to measure the length of the genes. I have taken the complete sequence of the genes, but a more accurate methodology would have been to measure the length of the total exons per gene, excluding introns. (I will conduct this analysis in the future and comment on the results in a separate blog post.)

The fact that we did not see any relation between gene length and the intolerance score could be explained because RVIS ranks genes in terms of their likelihood to influence disease, ignoring variants that, though disruptive, do not produce any phenotype. (This is to be discussed with Ben.) Another analysis we could perform is comparing the score provided by PolyPhen-2 or a similar tool for all human genes against the length of all human genes. This is, in fact, mentioned in the discussion of the paper.


Difficulties I have found during performing this analysis.




When two data frames are merged, we need to ensure that the common column between them has the same values (in this case, gene names). I have found two issues. First, the same genes can be referred to in more than one way. If this happens, these genes will be deleted in the merged table (the data frame that contains information from the two data frames we want to link). To avoid this problem, we can configure the algorithm to display the genes that did not match, and then consider the reason for this discrepancy. The second issue I have found is similar to the first: not only is the algorithm incapable of identifying genes with different names, but even if the difference is minimal, such as a capital letter or a white space, it is considered a mismatch. In other words, the values of the two common columns have to be absolutely identical; otherwise, the program will not identify the gene, and that gene will be eliminated. This is significant because it is a source of information loss.


Reflection: How can this analysis have a positive impact on patient's health?




Two elements can be considered in this short analysis. First, any tool or data that assists in the interpretation of personal genomes is welcome, and RVIS is a significant contribution in this regard. My brief analysis performed here does not have a direct impact, as it is for learning purposes; however, the skills developed during this activity can be applied in future practice. For example, scripts like those developed in this activity can be used in clinical trials when large data frames with patient information are combined to find unexpected relationships between variables. An example might be patients undergoing treatment for one pathology who end up discovering beneficial effects for other, seemingly unrelated, pathologies. These kinds of studies are now possible due to the development of new technologies that enable us to store massive amounts of information, as well as the creation of new algorithms such as machine learning or deep learning that enable us to find relationships between seemingly unrelated variables.

More information about what can be studied with personal health data can be found in the following link. As a consequence, this data is becoming increasingly valuable. To read about the value of personal health data, the following news article provides some insights.